Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

uniQure begins phase I study in acute intermittent porphyria

Dec. 13, 2012

PDC Biotech completes phase I trial of PDC-13 in primary dysmenorrhea

Dec. 13, 2012

Catabasis Pharmaceuticals synthesizes novel inhibitors of NF-kappaB signaling

Dec. 13, 2012

New agents for obesity presented by Zafgen

Dec. 12, 2012

Isis Pharmaceuticals reports phase I data for three drugs

Dec. 11, 2012

Protalix initiates study of long-term enzyme replacement therapy for Fabry's disease

Dec. 11, 2012

Gedeon Richter synthesizes novel MCH1 receptor antagonists

Dec. 11, 2012

New triacylglycerol lipase inhibitors designed by Roche

Dec. 10, 2012

AEM-28 given orphan drug status by FDA

Dec. 10, 2012

Lipocine cleared to conduct phase III study of oral testosterone replacement product

Dec. 10, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...